Hepatic subcapsular hematoma A rare complication post-ERCP; a case report

By -

 

Executive Summary

Endoscopic retrograde cholangiopancreatography (ERCP) is a cornerstone of modern gastroenterology, primarily utilized for therapeutic management of biliary and pancreatic diseases. While generally safer and more cost-effective than surgical alternatives, it carries the highest complication rate of all endoscopic procedures, estimated at approximately 10.6%.

This briefing document examines a rare but critical complication: Hepatic Subcapsular Hematoma (HSH). First described in 2000, HSH is often underdiagnosed but carries a significant fatality rate of approximately 7.5%. It is characterized by sudden abdominal pain and hemodynamic instability following ERCP. Diagnosis is confirmed via Computed Tomography (CT) or Ultrasound (US). While stable patients can be managed conservatively with prophylactic antibiotics, unstable cases require urgent surgical intervention or arterial embolization. The following analysis details the clinical presentation, suspected pathophysiology, and management protocols for HSH based on recent clinical reporting.

1. Overview of ERCP and Associated Risks

ERCP has evolved from a diagnostic tool to a primarily therapeutic procedure due to its inherent risks. Despite its minimally invasive nature, it is associated with several well-documented complications.

Complication Statistics

  • Overall Complication Rate: ~10% (specifically 10.6% according to multicentric Japanese registry data).

  • 30-Day Mortality Rate: 1.1%.

  • Standard Complications:

    • Acute pancreatitis.

    • Post-sphincterotomy bleeding (occurs in ~2% of cases).

    • Duodenal perforation.

    • Infection (e.g., cholangitis).

Hepatic Subcapsular Hematoma (HSH)

HSH is an exceptionally rare complication. Since its first description in 2000, only a limited number of case reports have been documented. The incidence is likely underestimated because most patients do not receive post-procedural imaging or laboratory monitoring unless symptoms are severe.

2. Clinical Case Analysis: A 79-Year-Old Female

The following case study illustrates the rapid and fatal progression of HSH post-ERCP.

Admission and Diagnosis

A 79-year-old female presented with right upper quadrant (RUQ) pain, nausea, and fever (38.2°C).

  • Imaging (Echography/MRCP): Identified a thickened gallbladder wall, dilated common bile duct (12 mm), and multiple stones, including a 10 mm stone in the proximal duct.

  • Initial Lab Results: Hemoglobin 10.4 g/dL; elevated white blood cell count (15,100).

Post-Procedural Complication

Twenty-four hours after a therapeutic ERCP and sphincterotomy, the patient's condition deteriorated sharply:

  • Symptoms: Sudden, sharp RUQ pain, paleness.

  • Vitals: Hypotension (80/40 mmHg) and tachycardia (120 bpm).

  • Laboratory Shift: Hemoglobin dropped from 10.4 g/dL to 6.4 g/dL.

  • Diagnostic Findings:

    • Upper GI Endoscopy: Ruled out bleeding at the sphincterotomy site.

    • CT Scan: Revealed a 37 mm thick HSH involving the right hepatic lobe and perisplenic fluids indicating intra-abdominal ascites.

Outcome

Despite intensive care, mechanical ventilation, and multiple transfusions, the patient developed acute kidney failure (anuria), hyperkalemia, and liver failure. The patient passed away on day 4 post-ERCP.

3. Pathophysiology and Causes

The exact etiology of HSH remains under investigation, but the source context identifies two primary theories:

Theory

Mechanism

Vascular Injury

Accidental injury to the biliary tree vasculature caused by the guide wire during the procedure.

Tractional Pressure

Pressure generated during biliary clearance using a balloon leads to the rupture of small biliary blood vessels, causing intraparenchymal hemorrhage and subcapsular collection.

4. Diagnosis and Management

Diagnostic Indicators

HSH should be suspected in any patient who has undergone ERCP and subsequently develops:

  1. Sudden, sharp abdominal pain.

  2. Significant drop in hemoglobin levels.

  3. Hemodynamic instability (hypotension and tachycardia).

  4. Laboratory instability.

Note: Diagnosis typically occurs within 24 hours but may be delayed up to 10 days post-procedure.

Management Protocols

The treatment approach is dictated by the patient's hemodynamic stability:

  • Conservative Management:

    • Reserved for persistently stable patients.

    • Includes close monitoring and prophylactic antibiotics to prevent the hematoma from becoming infected.

  • Interventional Management:

    • Arterial Embolization: Targeted closure of involved vessels via radiology.

    • Surgical Intervention: Required for unstable patients, those with a ruptured HSH, or those presenting with peritonitis. This involves drainage of the hematoma and hemostasis.

5. Conclusion and Lessons for Clinical Practice

Hepatic subcapsular hematoma is a rare but "very rare but fatal" complication. While outcomes are generally positive if the condition is diagnosed early and managed appropriately, the high fatality rate (7.5%) necessitates extreme vigilance.

Key takeaway: Early imaging (CT or US) is essential for any post-ERCP patient presenting with sharp abdominal pain and falling hemoglobin to rule out HSH, even if standard bleeding sites (like the sphincterotomy) appear clear.